Costs of hospital-based methadone maintenance treatment in HIV/AIDS control among injecting drug users in Indonesia. 2010

Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
Intergrated Management for Prevention and Control and Treatment of HIV/AIDS, Bandung, Indonesia.

OBJECTIVE To assess the cost of hospital-based methadone maintenance treatment (MMT) for injecting drug users (IDUs) in Bandung, Indonesia; to address concerns of financial sustainability at the hospital level and financial accessibility and economic attractiveness at the health care policy level. METHODS In a 1 year observation period in 2006-2007, MMT service delivery costs were estimated on the basis of a micro-costing approach. Patient costs were estimated on the basis of a survey among 48 methadone clients. RESULTS A total number of 129 clients attended the MMT clinic, resulting in a total of 16,335 client visits. Total annual societal costs of running the MMT clinic equalled Rp 1130 mln (US$123,672), or Rp 69,206 (US$7.57) per client visit. Of total costs, patient costs established the largest share (65%), followed by that of central government (20%), and the hospital (15%). Present consultation tariffs already cover hospital costs and the patient costs of accessing MMT services constitute almost 70% of their income. CONCLUSIONS Under current circumstances, MMT services are financially sustainable to the hospital. MMT services are subsidized by the central government, and this is warranted considering the important role of the program in HIV/AIDS among IDUs. Still, the present user fee seems a barrier to utilization, and a higher level of subsidy might be justified to reduce the cost to the patient.

UI MeSH Term Description Entries
D007214 Indonesia A republic stretching from the Indian Ocean east to New Guinea, comprising six main islands: Java, Sumatra, Bali, Kalimantan (the Indonesian portion of the island of Borneo), Sulawesi (formerly known as the Celebes) and Irian Jaya (the western part of New Guinea). Its capital is Djakarta. The ethnic groups living there are largely Chinese, Arab, Eurasian, Indian, and Pakistani; 85% of the peoples are of the Islamic faith. Celebes,Indonesian New Guinea,Irian Jaya,Java,Madoera,Netherlands East Indies,New Guinea, Indonesian,New Guinea, West,Sulawesi,Sumatra,Timor,West Irian,Bali,East Indies,Madura,Malay Archipelago
D008297 Male Males
D008691 Methadone A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) Amidone,Biodone,Dolophine,Metadol,Metasedin,Methaddict,Methadone Hydrochloride,Methadose,Methex,Phenadone,Phymet,Physeptone,Pinadone,Symoron,Hydrochloride, Methadone
D003362 Cost-Benefit Analysis A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. In contrast a cost effectiveness in general compares cost with qualitative outcomes. Cost and Benefit,Cost-Benefit Data,Benefits and Costs,Cost Benefit,Cost Benefit Analysis,Cost-Utility Analysis,Costs and Benefits,Economic Evaluation,Marginal Analysis,Analyses, Cost Benefit,Analysis, Cost Benefit,Analysis, Cost-Benefit,Analysis, Cost-Utility,Analysis, Marginal,Benefit and Cost,Cost Benefit Analyses,Cost Benefit Data,Cost Utility Analysis,Cost-Benefit Analyses,Cost-Utility Analyses,Data, Cost-Benefit,Economic Evaluations,Evaluation, Economic,Marginal Analyses
D005260 Female Females
D006556 Heroin Dependence Strong dependence or addiction, both physiological and emotional, upon HEROIN. Heroin Abuse,Heroin Addiction,Heroin Smoking,Abuse, Heroin,Addiction, Heroin,Dependence, Heroin,Heroin Smokings,Smoking, Heroin
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015819 Substance Abuse, Intravenous Abuse, overuse, or misuse of a substance by its injection into a vein. Drug Abuse, Intravenous,Drug Abuse, Parenteral,Intravenous Drug Abuse,Intravenous Substance Abuse,Parenteral Drug Abuse

Related Publications

Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
January 2012, AIDS care,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
January 1992, AIDS care,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
October 1996, Journal of epidemiology and community health,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
July 2009, Acta medica Indonesiana,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
September 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
July 2009, Acta medica Indonesiana,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
August 1997, Addiction (Abingdon, England),
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
October 1994, Drug and alcohol dependence,
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
April 2001, Journal of acquired immune deficiency syndromes (1999),
Irvan Afriandi, and Adiatma Y M Siregar, and Filip Meheus, and Teddy Hidayat, and Andre van der Ven, and Reinout van Crevel, and Rob Baltussen
January 2012, PloS one,
Copied contents to your clipboard!